In a swift, almost frenzied surge, cannabis stocks soared following Tuesday's news that the DEA intends to begin the process of moving marijuana from its onerous Schedule I designation to Schedule III.
One of the major benefits of this long-awaited move lies in the expected changes in the tax law.
If marijuana transitions from Schedule I to III, cannabis companies will be able to write off standard corporate deductions. That’s a benefit unfairly denied to them for years, forcing them to pay exorbitant taxes.
Green Market noted that some companies — Green Thumb Industries GTBIF, Verano Holdings VRNOF and Cresco Labs CRLBF — could boost their bottom lines by $70 million to $100 million potentially starting this year.
This rescheduling offers a much-needed reprieve for an industry beleaguered by plummeting prices, fierce competition, and burdensome taxes.
"Taxes were strangling these companies. Now all the sudden we're talking about a growth sector again," Morgan Paxhia told the outlet. As co-founder of Poseidon Asset Management, Paxhia has been a regular guest at Benzinga's Cannabis Capital Conferences.
Speaking of which, anyone wanting to learn more about the future of the cannabis industry and how or if it's a great time to invest should plan to attend the Benzinga Cannabis Capital Conference this October in Chicago. Hear directly from key industry players and policymakers. Get your tickets now by following this link, and access a 20% discount using the code JAVI20.
Cannabis Stock Short Sellers Get Clobbered
Short sellers with positions against the top 10 cannabis company stocks took up to $210 million in losses as stocks closed out on Tuesday with record gains. "The one-day rout wiped out all gains that the cohort had earned in April and extended year-to-date paper losses to nearly $240 million," noted Bloomberg, looking at data from S3 Partners LLC.
The biggest losses for short sellers were from two stocks: Tilray Brands Inc. TLRY, which jumped 40% and Canopy Growth Corporation CGC that led the gains as it skyrocketed by 78.8% to close at $14.88 per share. The trading frenzy pushed the volume to 79.25 million shares.
The short-selling pains notwithstanding, Paxhia sees the potential listing of cannabis companies on U.S. exchanges as significantly elevating their market value and potentially tripling or quintupling their worth compared to Canadian markets.
Image: Midjourney
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.